# Gene Therapy for DME

> **NCT06492876** · PHASE1,PHASE2 · RECRUITING · sponsor: **Frontera Therapeutics** · enrollment: 78 (estimated)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **GENETIC:** FT-003

## Key facts

- **NCT ID:** NCT06492876
- **Lead sponsor:** Frontera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2024-11-15
- **Final completion:** 2028-11-15
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06492876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06492876, "Gene Therapy for DME". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06492876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*